A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal
DRUG: RAD001, Cetuximab, Irinotecan
Dose Limiting Toxicities, each cycle was 21 days, at end of cycle 2
Pharmacokinetics of RAD001, Irinotecan and SN-38|Progressions Free Survival|Overall Survival|Objective Response Rate
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan